Business Description
Apogee Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US03770N1019
Total Employee Number:
261Description
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 142.24 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -60.9 | |||||
3-Year EPS without NRI Growth Rate | -42.4 | |||||
3-Year FCF Growth Rate | -85.2 | |||||
3-Year Book Growth Rate | 64.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -16.36 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.66 | |||||
9-Day RSI | 80.36 | |||||
14-Day RSI | 78.7 | |||||
3-1 Month Momentum % | 70.36 | |||||
6-1 Month Momentum % | 89.09 | |||||
12-1 Month Momentum % | 254.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 26.44 | |||||
Quick Ratio | 26.44 | |||||
Cash Ratio | 25.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.8 | |||||
Shareholder Yield % | -3.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -32.28 | |||||
ROA % | -30.34 | |||||
ROIC % | -154.57 | |||||
3-Year ROIIC % | -125.91 | |||||
ROC (Joel Greenblatt) % | -2209 | |||||
ROCE % | -33.75 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 8.52 | |||||
Price-to-Tangible-Book | 8.52 | |||||
EV-to-EBIT | -29.27 | |||||
EV-to-EBITDA | -29.42 | |||||
EV-to-Forward-Revenue | 370.32 | |||||
EV-to-FCF | -37.95 | |||||
| Price-to-Net-Current-Asset-Value | 11.97 | |||||
| Price-to-Net-Cash | 12.25 | |||||
Earnings Yield (Greenblatt) % | -3.42 | |||||
FCF Yield % | -2.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APGE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Apogee Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.34 | ||
| Beta | -0.1221 | ||
| 3-Year Sharpe Ratio | 1.03 | ||
| 3-Year Sortino Ratio | 2.8 | ||
| Volatility % | 73.73 | ||
| 14-Day RSI | 78.7 | ||
| 14-Day ATR ($) | 0.349495 | ||
| 20-Day SMA ($) | 134.7245 | ||
| 12-1 Month Momentum % | 254.17 | ||
| 52-Week Range ($) | 35.39 - 135.09 | ||
| Shares Outstanding (Mil) | 75.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Apogee Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Apogee Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-02 | In 180 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-02 | In 180 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 68 days | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 134.84 (+0.14%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 09:20 | 85.00 (+1.58%) | ||
| General meeting for 2026 | 2026-06-09 11:00 | 83.01 (-4.97%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 11:40 | 78.71 (+2.09%) | ||
| Part B 16-week data from the Phase 2 APEX trial of zumilokibart | 2026-05-27 08:00 | 82.81 (+0.69%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 83.03 (+0.33%) | ||
| APEX Phase 2 Part A 52-Week Results for Zumilokibart (APG777) | 2026-03-23 08:00 | 66.04 (-2.97%) |
Show
Entries
Apogee Therapeutics Inc Frequently Asked Questions
What is Apogee Therapeutics Inc(APGE)'s stock price today?
The current price of APGE is $135.09. The 52 week high of APGE is $135.09 and 52 week low is $35.39.
When is next earnings date of Apogee Therapeutics Inc(APGE)?
The next earnings date of Apogee Therapeutics Inc(APGE) is 2026-11-10 Est..
Does Apogee Therapeutics Inc(APGE) pay dividends? If so, how much?
Apogee Therapeutics Inc(APGE) does not pay dividend.
Guru Commentaries on NAS:APGE
Baron Health Care Fund
Bearish
2026 Q2
Baron Health Care Fund
· 43 holdings
What the manager wrote
During the quarter, we sold Apogee Therapeutics, Inc. following the announcement that it was being acquired by AbbVie Inc. for $135.11 per share, representing a 49.5% premium over the prior day’s closing stock price. This acquisition reflects our view that Apogee was an attractive target, but we believe that the sale indicates a lack of further growth potential as a standalone entity.
Press Release
Articles on Apogee Therapeutics Inc
APGE SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing
Aug 11, 2026
Will Apogee Therapeutics (APGE) Overcome Its Challenges After Reporting Q2 Loss of $85.9 Million? GF Score: 22/100
Aug 10, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers